Grade 3b Follicular Lymphoma Clinical Trial
Official title:
MK-3475 in Combination With Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma
This pilot phase I trial studies the side effects of pembrolizumab and combination chemotherapy in treating patients with previously untreated diffuse large B-cell lymphoma or grade 3b follicular lymphoma. Monoclonal antibodies, such as pembrolizumab and rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab together with combination chemotherapy may be with a better treatment for diffuse large B-cell lymphoma or follicular lymphoma.
PRIMARY OBJECTIVES:
I. To measure the toxicity profile of pembrolizumab (MK-3475) when co-administered with
full-course RCHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine
sulfate, and prednisone) in subjects with previously untreated diffuse large B-cell lymphoma
(DLBCL).
SECONDARY OBJECTIVES:
I. To assess clinical outcomes including response rate, event-free survival, and overall
survival after MK-3475 + RCHOP induction for subjects with previously untreated DLBCL.
TERTIARY OBJECTIVES:
I. To measure baseline expression of proteins in the programmed death-1 (PD-1) family on
tumor cells and coexisting immune infiltrates, using archival tissue when available.
II. To measure peripheral blood T cell subsets before and after treatment using flow
cytometry, and to measure baseline vitamin D (25-hydroxy, total).
III. To explore relationships with these parameters and likelihood of response to therapy and
outcomes.
OUTLINE:
Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 and prednisone
orally (PO) on days 1-5. Patients also receive rituximab IV, cyclophosphamide IV, doxorubicin
hydrochloride IV, and vincristine sulfate IV on day 2 of course 1 and on day 1 of subsequent
courses. Treatment repeats every 21 days for 6 courses in the absence of disease progression
or unacceptable toxicity.
After completion of the study treatment, patients are followed up to 5 years.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05890352 -
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
|
Phase 2 | |
| Recruiting |
NCT06026319 -
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
|
Phase 1 | |
| Not yet recruiting |
NCT02927717 -
An Italian Experience on Grade 3b Follicular Lymphoma
|
N/A | |
| Recruiting |
NCT04799275 -
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
|
Phase 2/Phase 3 | |
| Terminated |
NCT04156828 -
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05583149 -
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
|
Phase 2 | |
| Recruiting |
NCT05633615 -
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT03150329 -
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
|
Phase 1 | |
| Recruiting |
NCT05455697 -
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
|
Phase 1/Phase 2 | |
| Approved for marketing |
NCT05733650 -
Expanded Access Program for Epcoritamab
|